– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – This clinical trial is designed based on the results of an ...

The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...

Graphical Abstract. Relative survival with and without radioiodine therapy (RAI) in intermediate risk papillary thyroid cancer (PTC) and low risk, minimally invasive follicular thyroid cancer (FTC). A ...

July 4, 2008 — The experimental drug motesanib (under development by Amgen) has shown activity in progressive advanced thyroid cancer in a phase 2 trial in 93 patients. This is one of the largest ...

There is no universally accepted definition for recurrence of differentiated thyroid cancer (DTC) across treatment categories such as total thyroidectomy with or without radioactive iodine ablation ...

An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid ...

Postoperative radioiodine (RAI) versus no radiodine therapy for patients with low-risk differentiated thyroid cancer: A systematic review and meta-analysis. Survival outcomes in radioactive ...

Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...

Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer ...